Mitochondrial, lysosomal and DNA damages induced by acrylamide attenuate by ellagic acid in human lymphocyte (2024)

Journal List
PLoS One
PMC7909646

As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsem*nt of, or agreement with, the contents by NLM or the National Institutes of Health.
Learn more: PMC Disclaimer | PMC Copyright Notice

PLoS One. 2021; 16(2): e0247776.

Published online 2021 Feb 26. doi:10.1371/journal.pone.0247776

PMCID: PMC7909646

PMID: 33635915

Ahmad Salimi, Conceptualization, Formal analysis, Funding acquisition, Investigation, Methodology, Software, Supervision, Writing – original draft, Writing – review & editing,^1,^2,^* Elahe Baghal, Data curation,^1,³ Hassan Ghobadi, Writing – review & editing,⁴ Niloufar Hashemidanesh, Data curation,^1,³ Farzad Khodaparast, Data curation,^1,³ and Enayatollah Seydi, Formal analysis, Software, Writing – original draft^5,^6,^*

Soumen Bera, Editor

Author information Article notes Copyright and License information PMC Disclaimer

Associated Data

Supplementary Materials

Data Availability Statement

Abstract

Acrylamide (AA), is an important contaminant formed during food processing under high temperature. Due to its potential neurotoxicity, reproductive toxicity, hepatotoxicity, immunotoxicity, genotoxicity and carcinogenicity effects, this food contaminant has been recognized as a human health concern. Previous studies showed that acrylamide-induced toxicity is associated with active metabolite of acrylamide by cytochrome P450 enzyme, oxidative stress, mitochondrial dysfunction and DNA damage. In the current study, we investigated the role of oxidative stress in acrylamide’s genotoxicity and therapeutic potential role of ellagic acid (EA) in human lymphocytes. Human lymphocytes were simultaneously treated with different concentrations of EA (10, 25 and 50 μM) and acrylamide (50 μM) for 4 h at 37°C. After 4 hours of incubation, the toxicity parameters such cytotoxicity, ROS formation, oxidized/reduced glutathione (GSH/GSSG) content, malondialdehyde (MDA) level, lysosomal membrane integrity, mitochondria membrane potential (ΔΨm) collapse and 8-hydroxy-2’-deoxyguanosine (8-OHdG) were analyzed using biochemical and flow cytometry evaluations. It has been found that acrylamide (50 μM) significantly increased cytotoxicity, ROS formation, GSH oxidation, lipid peroxidation, MMP collapse, lysosomal and DNA damage in human lymphocytes. On the other hand, cotreatment with EA (25 and 50 μM) inhibited AA-induced oxidative stress which subsequently led to decreasing of the cytotoxicity, GSH oxidation, lipid peroxidation, MMP collapse, lysosomal and DNA damage. Together, these results suggest that probably the co-exposure of EA with foods containing acrylamide could decrease mitochondrial, lysosomal and DNA damages, and oxidative stress induced by acrylamide in human body.

Introduction

One of heat-induced toxic substances in during food processing techniques is acrylamide (AA) that has recently received much scientific interest [1]. In the past, acrylamide was found in many industrial processes, such as in the manufacture of paper, glues, plastics, in the treatment of drinking water and wastewater and as a component in the cigarette smoke [2]. For the first time in April 2002, acrylamide was also reported by Swedish researchers in consumer products, particularly starchy foods such as grain products and potato [3]. The Stockholm University and Swedish National Food Administration (SNFA) researchers detected high levels (150–4,000 mg/kg) and moderate levels (5–50 mg/kg) of acrylamide in heated carbohydrate-rich and protein foods, respectively [4]. Exposure humans to acrylamide can be occurred through inhalational, dermal, and oral routes [1]. Due to wide range of acrylamide exposure sources diet, drinking water, smoking, and environmental/occupational sources, many people can be exposed to this chemical through oral, dermal or inhalation [1,5,6]. After exposure, it is showed that acrylamide is completely and rapidly absorbed and distributed to the peripheral tissues in animals and humans [7]. A study in healthy volunteers have showed that acrylamide is able to reach any human tissue. In the body acrylamide is metabolized to glycidamide as active metabolite by the cytochrome P450 enzyme (CYP450), where is known to be more reactive toward macromolecules such proteins, lipids and DNA than the parent acrylamide compound [8]. Acrylamide is associated with a wide range of different toxicities in human and animal such as neurotoxicity, reproductive toxicity, hepatotoxicity, immunotoxicity, genotoxicity and carcinogenicity [9]. Also, this substance has been categorized as a probable human carcinogen by the International Agency for Research on Cancer (IARC) [10]. Due to definite exposure of humans to acrylamide for various sources, probably detoxification of this compound inside the body can be a suitable approach to reduce its toxicity. It is well confirmed that oxidative stress and mitochondrial dysfunction have a main role in acrylamide-induced toxicity [11]. Therefore, natural compounds with antioxidant and antitumorigenic properties can probably play a promising role in inhibiting the toxicity caused by acrylamide.

Natural products extracted from plants have been demonstrated to reverse acrylamide-induced toxicity [9]. For example, chrysin as plant-derived natural product, reduced acrylamide-induced neurotoxicity in Wistar rats due to its high antioxidant properties [12]. Also, quercetin is able to protect against acrylamide-induced neurotoxicity [13]. Berry juices significantly enhance the growth of acrylamide-exposed yeast cells, and decreased the level of ROS [14]. Ellagic acid (EA) as a plant-derived natural product found in pomegranate (Punica granatum) and the family of ellagitannins (ETs) has different pharmacological effects [15]. Ellagic acid has generated a noticeable scientific interest because of beneficial health effects against many oxidative-linked diseases, including neurodegenerative and cancer diseases [15]. It has been reported that ellagic acid can prevent of oxidative stress, inflammation, and histopathological alterations in acrylamide-induced hepatotoxicity in wistar rats [16]. Also, et al at 2019 reported that ellagic acid has neuroprotective effects against acrylamide-induced neurotoxicity in rats [17]. Due to the promising effect of ellagic acid on the oxidative stress, genotoxicity and cytotoxicity, it deserves to be more studded. Therefore, in the current study for the first time we evaluate the effect of ellagic acid against acrylamide-induced toxicity in primary lymphocytes obtained from humans.

Materials and methods

Chemicals

MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, 2′,7′-dichlorofuorescin diacetate (DCFH-DA), Rhodamine123, Bovine Serum Albumin (BSA), Trypan blue, Acridine Orange, N-(2-hydroxyethyl) piperazine-N′-(2-ethanesulfonic acid) (HEPES), Acrylamide with CAS-Nummer: 79-06-1 (A9099), Ellagic Acid, Fetal Bovine Serum (FBS), 2-mercaptoethanol and Antibiotic-Antimycotic Solution were obtained from the Sigma Chemical Co. RPMI1640 was purchased from GIBCO (USA). Ficoll-paque PLUS was provided from Ge Healthcare Bio-Science Company.

Sample collection and ethic statement

The study was performed by using isolated human lymphocytes as primary cells from 10 healthy, young (20–24 years) subjects (four men and six women). The criteria of acceptability to ensure reliability of the experiment were: receiving any medical therapy, from non-smoker and non-alcoholic persons, without serious illness and having good health. The choice of healthy volunteers was performed at the Internal Medicine Department (Pulmonary Division), Faculty of Medicine, Ardabil University of Medical Sciences, under the guidance of an expert physician (Hassan Ghobadi). Before blood sampling, the informed consent form was signed by the participants. This project was performed in Ardabil University of Medical Sciences at school of pharmacy. The dedicated approved ethical code by research ethic committee of Ardabil University of Medical Sciences for this study is IR.ARUMS.REC.1398.496.

Lymphocytes isolation

Peripheral blood obtained from young donors were used for isolation of lymphocytes. Briefly, 5 ml of blood containing anticoagulant was gently mixed with 5 ml of normal saline in a 15 ml sterile tube. Then 5 ml of diluted blood was added to two sterile tube contains 3 ml of Ficoll-paque PLUS and centrifuged at 2500 rpm at 4 C° for 20 min. After centrifugation, the buffy coat was isolated and added to a new sterile falcon tube. The buffy coat was centrifuged at 1500 rpm at 4 C° for 10 min, and the pellet was suspended in erythrocyte lysis buffer and incubated at 37°C for 5 min. After centrifugation, the supernatant was discarded, and the pellet were washed with RPMI1640 supplemented with 10% fetal bovine serum (FBS) and l-glutamine and centrifuged at 2000g for 7 min. The isolated cells were resuspended in RPMI1640 medium supplemented with L-glutamine and 10% FBS at 37°C in normal condition with a humidified atmosphere and 5% CO₂. Before the experiments, the number of live cells was measured by Trypan Blue and the cell viability was more than 95%. The lymphocyte density used in the tests was 10×10⁶ cells/ml [18].

Treatment of isolated lymphocytes

For all experiments isolated lymphocytes were cultured in RPMI1640 with supplemented l-glutamine and 10% FBS at 37°C with 5% CO₂ in a humidified atmosphere. After the initial period of incubation, isolated lymphocytes were treated with dimethyl sulfoxide (DMSO) (.05%) as control group, IC₅₀ 4h acrylamide, IC₅₀ 4h acrylamide + 10μM EA, IC₅₀ 4h acrylamide + 25μM EA, IC₅₀ 4h acrylamide + 50μM EA and 50μM EA at 37°C. Each experiment included a positive control (data not shown).

Measurement of cell viability

Briefly, isolated lymphocytes (10⁴ cells per well) were incubated in 96-well culture plates in 100 μl of RPMI1640 supplemented with l-glutamine and 10% FBS at 37°C with 5% CO₂ in a humidified atmosphere for 4 hours according to the above grouping. After treatment 25 μl of MTT (0.5 mg/ml) was added to each well. After the 4 h incubation at 37°C, 100 ml of DMSO was added to dissolve the water-insoluble formazan salt. Then, the absorbance at λ = 570 nm was measured with an ELISA microplate reader. The viability was represented as the percentage absorbance compared with untreated control group. Each experiment was performed three times [19].

Measurement of reactive oxygen species

The intracellular ROS formation was measured using 2′,7′-dichlorofuorescin diacetate (DCFH-DA). Inside the cells DCFH-DA hydrolyzed to the nonfluorescent DCFH by using intracellular esterase, which in the presence of ROS, could be rapidly oxidized to the highly fluorescent 2,7-dichlorofluorescein (DCF). After treatment for 4 hours according to the above grouping, the isolated lymphocytes were washed with PBS and incubated with DCFH-DA at a final concentration of 5 μM for an additional 20 min at 37°C in the dark. The isolated lymphocytes that were previously stained with DCFH-DA were separated from the medium by 1 min centrifugation at 1000 rpm. To remove the additional DCFH-DA from the medium the cell washing was performed twice using PBS. The fluorescent intensity of the cell suspensions was measured by flow cytometry (Cyflow Space-Partec, Germany) and mean of fluorescence intensities were analyzed by software (FlowJo) [20]. The results were expressed as fluorescent intensity per 10⁴ cells

Measurement of mitochondrial membrane potential collapse

To monitor the membrane potential of mitochondria we used rhodamine 123 as a fluorescent probe. This fluorescent probe is lipophilic cation accumulated by mitochondria in proportion to ΔΨ. Upon accumulation, rhodamine 123 exhibit a red shift in both its absorption and fluorescence emission spectra. The fluorescence intensity is quenched when the dye is accumulated by mitochondria. Briefly, after treatment for 4 hours according to the above grouping, the isolated lymphocytes were washed with PBS and incubated with rhodamine 123 at a final concentration of 5 μM for an additional 20 min at 37°C in the dark. The isolated lymphocytes that were previously stained with rhodamine 123, were separated from the medium by 1 min centrifugation at 1000 rpm. To remove the additional rhodamine 123 from the medium the cell washing was performed twice using PBS. The fluorescent intensity of the cell suspensions was measured by flow cytometry (Cyflow Space-Partec, Germany) and mean of fluorescence intensities were analyzed by software (FlowJo). The results were expressed as fluorescent intensity per 10⁴ cells [21].

Measurement of lysosomal membrane destabilization

Acridine orange was used to measure lysosomal membrane destabilization as described previously [22]. Acridine orange, a lysosomotropic weak base, accumulates in lysosome on the basis of proton trapping and emits red fluorescence in intact lysosomes with high concentrations, acridine orange and emits green fluorescence in the cytosol and the nucleus with low concentrations [23]. Therefore, lysosomal membrane destabilization can be determined by detecting changes in either green fluorescence or red fluorescence. Briefly, after treatment for 4 hours according to the above grouping, the isolated lymphocytes were washed with PBS and incubated with acridine orange at a final concentration of 5 μM for an additional 20 min at 37°C in the dark. The isolated lymphocytes that were previously stained with acridine orange were separated from the medium by 1 min centrifugation at 1000 rpm. To remove the additional acridine orange from the medium the cell washing was performed twice using PBS. The fluorescent intensity of the cell suspensions was measured by flow cytometry (Cyflow Space-Partec, Germany) and mean of fluorescence intensities were analyzed by software (FlowJo). The results were expressed as fluorescent intensity per 10⁴ cells [21].

Measurement of lipid peroxidation

The content of malondialdehyde (MDA) as by-product of lipid peroxidation, was determined by the thiobarbituric acid (TBA) reactive substances during an acid-heating reaction. The MDA-TBA adduct can be easily quantified calorimetrically at 532 nm. Briefly, after treatment for 4 hours according to the above grouping, the isolated lymphocytes were washed with PBS, and then mechanically lysed by hom*ogenizer in a tube containing 1 ml 0.1% (w/v) trichloroacetic acid (TCA). The micro tubes containing hom*ogenized samples were centrifuged at 10,000 x g for 10 min and the supernatant transferred to new tube containing 4 ml of TBA reagent (containing 20% TCA and 0.5% TBA). Then all the micro tubes were placed in a boiling water bath for 15 min and after quick cooling on ice, the mixture was centrifuged again at 1000 × g for 10 min. The content of MDA in each tube was measured by the absorbance of the supernatant at 532 nm with an ELISA reader [24].

Measurement of GSH and GSSG contents

GSH and GSSG levels in treated isolated lymphocytes were evaluated using 5, 5’-dithiobis-2-nitrobenzoic acid (DTNB) as the indicator and spectrophotometer method for measurement of GSH and GSSG contents [25]. Briefly, after treatment for 4 hours according to the above grouping, the isolated lymphocytes were washed with PBS twice and mechanically lysed by hom*ogenizer resuspended in 1 mL of 0.1 mol/L phosphate buffer (pH 7.4). The lysate was centrifuged at 8,000 × g at 4°C for 10 min and supernatant was collected. For assessment of GSH, 100 μl supernatant was mixed with 3 ml 500 mM TRIS–HCl (pH 8.0) buffer containing 10 mM DTNB and incubated at 25°C for 15 min and for assessment of GSSG, 100 μl of supernatant was added to 3 ml of reaction solution containing glutathione reductase (1 U for each 3 ml reaction solution), 500 mM TRIS–HCl (pH 8.0) buffer, 150 μM NADPH, 1 mM EDTA, 3 mM MgCl2, then was add 100 mM DTNB to a final concentration of 10 mM and incubate at room temperature for 15 min. The produced yellow color was read at 412 nm on a spectrophotometer. GSH and GSSG contents were observed as μM [25].

Determination of 8-hydroxy-2’-deoxyguanosine (8-OHdG)

Briefly, after treatment for 4 hours according to the above grouping, the cellular DNA was isolated using a DNA extraction kit (iNtRON Biotechnology Inc., Sungnam, Republic of Korea), following the manufacturer’s protocol, and quantified. The quantity of 8-OHdG, was determined by kit (OXIS Health Products Inc., Portland, OR, USA) following the manufacturer’s protocol and by a calculation on a standard curve measured at 450 nm absorbance using a microplate reader.

Statistical analysis

Results are presented as mean ± standard deviation. All statistical analyses were performed using the GraphPad Prism version 5. Statistical significance was determined using the one-way ANOVA test, followed by the post-hoc Tukey test. Statistical significance was set at P < 0.05. Also, the flow cytometric data was obtained with Cyflow Space-Partec and analyzed by FlowJo software. All experiments were carried-out in triplicate.

Results

EA attenuated acrylamide induced cytotoxicity in isolated lymphocytes

The protection of EA on isolated lymphocytes treated with acrylamide was detected by MTT assay, after being treated with EA with different concentrations (10, 25 and 50μM) and acrylamide (50) for 4 h. Compared with the control group, the cell viability in acrylamide (25, 50 and 100 μM) groups was decreased significantly (Fig 1A), but not in the lower concentration groups (1, 5 and 10 μM). Compared with acrylamide (50 μM) group, EA (25 and 50 μM) increased cell viability, especially significant in 50 μM EA group (Fig 1B). The concentrations of EA (10, 25 and 50 μM) were picked for further assay. No significant decrease in the lymphocyte viability was observed when the cells were treated with 50 μM EA alone.

Mitochondrial, lysosomal and DNA damages induced by acrylamide attenuate by ellagic acid in human lymphocyte (2)

Open in a separate window

Fig 1

Ellagic acid reduces cytotoxicity effects of AA in human lymphocytes.

(A) Representative MTT assay of human lymphocytes treated with AA in a range of 1 μM to 100 μM (10,000 cells per well, n = 3 technical replicates; independent experiments repeated at least 3 times) at 4 hours. (B) Representative MTT assay of human lymphocytes treated with AA (50 μM) and EA in a range of 10 μM to 50 μM (10,000 cells per well, n = 3 technical replicates; independent experiments repeated at least 3 times) at 4 hours. Data are presented as mean ± SD, n = 3, ***p < 0.001: Control versus AA; #p < 0.05, ##p < 0.01: AA + EA versus AA-treated human lymphocytes ANOVA, Tukey’s test.

EA mitigated the ROS formation induced by acrylamide in isolated lymphocytes

To measure the effect of EA on acrylamide-induced oxidative stress in isolated lymphocytes, the level of ROS was measured through DCFH-DA fluorescence by flow cytometry. Results showed that acrylamide (50 μM) increased ROS levels significantly, while EA (25 and 50 μM) achieves anti-oxidative effect by reducing ROS formation (Fig 2A). No significant changes in the lymphocyte ROS formation were observed when the isolated lymphocytes were treated with EA (50 μM) as compared with control group. Buyhylatedhydroxy toluene (BHT) as an antioxidant for confirmation of antioxidant effect of ellagic acid was used (data not shown).

Mitochondrial, lysosomal and DNA damages induced by acrylamide attenuate by ellagic acid in human lymphocyte (3)

Open in a separate window

Fig 2

Ellagic acid decreases ROS formation.

ROS formation was analyzed by means of fluorescence intensity of DCFH-DA following AA exposure (4 hours) in the presence or absence of EA (10, 25 and 50 μM) in human lymphocytes. Bar graphs with statistics. Data are presented as mean ± SD, n = 3, independent experiments repeated at least 3 times, ***p < 0.001: Control versus AA; ##p < 0.01: AA + EA versus AA-treated human lymphocytes ANOVA, Tukey’s test.

EA alleviated acrylamide-induced mitochondria injury in isolated lymphocytes

To evaluate the mitochondrial function in isolated lymphocytes, the mitochondrial membrane potential (ΔΨm) was measured by rhodamine 123 staining. As shown in Fig 3, acrylamide (50 μM) markedly enhanced fluorescence intensity of rhodamine 123, while EA (25 and 50 μM) treatment partly decreased the fluorescence intensity. It showed that EA significantly alleviated acrylamide-induced mitochondrial membrane potential depolarization and optimized the mitochondrial membrane potential status. Also, no significant alteration in MMP collapse was observed when the isolated lymphocytes were treated with 50 μM EA alone as compared with control group.

Mitochondrial, lysosomal and DNA damages induced by acrylamide attenuate by ellagic acid in human lymphocyte (4)

Open in a separate window

Fig 3

Ellagic acid decreases mitochondrial damages.

Mitochondrial membrane potential collapse was analyzed by means of fluorescence intensity of rhodamine 123 as a cationic dye following AA exposure (4 hours) in the presence or absence of EA (10, 25 and 50 μM) in human lymphocytes. Bar graphs with statistics. Data are presented as mean ± SD, n = 3, independent experiments repeated at least 3 times, ***p < 0.001: Control versus AA; ##p < 0.01, ###p < 0.001: AA + EA versus AA-treated human lymphocytes ANOVA, Tukey’s test.

EA alleviated acrylamide-induced lysosomal damages in isolated lymphocytes

To evaluate the lysosomal damages in isolated lymphocytes, the lysosomal membrane destabilization was measured by acridine orange staining. As shown in Fig 4, acrylamide (50 μM) markedly enhanced fluorescence intensity of acridine orange as an indicator of lysosomal damages, while EA (25 and 50 μM) treatment partly decreased the fluorescence intensity of acridine orange. It showed that EA significantly alleviated acrylamide-induced lysosomal damages. Also, no significant alteration was observed when the isolated lymphocytes were treated with 50 μM EA alone as compared with control group.

Mitochondrial, lysosomal and DNA damages induced by acrylamide attenuate by ellagic acid in human lymphocyte (5)

Open in a separate window

Fig 4

Ellagic acid decreases lysosomal integrity.

Lysosomal integrity was analyzed by means of fluorescence intensity of acridine orange following AA exposure (4 hours) in the presence or absence of EA (10, 25 and 50 μM) in human lymphocytes. Bar graphs with statistics. Data are presented as mean ± SD, n = 3, independent experiments repeated at least 3 times, ***p < 0.001: Control versus AA; #p < 0.05: AA + EA versus AA-treated human lymphocytes ANOVA, Tukey’s test.

EA mitigated acrylamide-induced glutathione depletion in isolated lymphocytes

The levels of GSH and GSSG significantly increased and decreased respectively in the isolated lymphocytes exposed with acrylamide (50 μM). A significant increase in GSH content and a significant decrease in GSSG was seen when the isolated lymphocytes treated with EA (25 and 50 μM) and acrylamide (50 μM) in comparison with acrylamide group, but did not observe significant different in the levels of GSH and GSSG when compared to the control group. EA (50 μM) alone did not show any change in the isolated lymphocytes GSH and GSSG content when compared with control group (Fig 5).

Mitochondrial, lysosomal and DNA damages induced by acrylamide attenuate by ellagic acid in human lymphocyte (6)

Open in a separate window

Fig 5

Addition of ellagic acid decreases AA-induced glutathione depletion in human lymphocytes.

(A) GSH content significantly decreased in AA-treated human lymphocytes while cotreatment EA (50 μM) with AA obviously increased the GSH content in human lymphocytes. (B) Also, AA significantly increased the GSSG content in human lymphocytes after 4 h of exposure while EA (50 μM) significantly decreased the GSSG content in the presence of AA. All experiments were repeated at least three times. ***p < 0.001: Control versus AA; #p < 0.05, ###p < 0.001: AA + EA versus AA-treated human lymphocytes ANOVA, Tukey’s test.

EA alleviated acrylamide-induced lipid peroxidation in Isolated lymphocytes

To evaluate the effects of acrylamide on lipid peroxidation, the intracellular levels of MDA were measured in isolated lymphocytes. The concentration of MDA increased from 67 nM in control cells to 102 in 50 μM acrylamide-treated group. However, EA treatment (25 and 50 μM) successfully attenuated the acrylamide-induced increases in intracellular MDA levels in isolated lymphocytes. Also, no significant changes in the intracellular MDA levels were observed when isolated lymphocytes were treated with 50 μM EA alone as compared with control group (Fig 6A).

The blockade of acrylamide-induced DNA damage by EA in isolated lymphocytes

We subsequently performed 8-hydroxy-2’-deoxyguanosine (8-OHdG) assay to determine whether EA reduces acrylamide-induced DNA damage. Results showed the acrylamide (50 μM) treatment significantly increased the production of the 8-OHdG adduct, an oxidative stress-induced DNA damage marker, compared to the control group, but the cotreatment with EA (25 and 50 μM) significantly reduced the production of 8-OHdG by acrylamide. EA (50 μM) alone did not show any change in the production of the 8-OHdG adduct in the isolated lymphocytes when compared with control group (Fig 6B).

Discussion

In many in vivo and in vitro studies have been reported genotoxicity, cytotoxicity, oxidative stress and mitochondrial dysfunction induced by acrylamide [26,27]. Various genotoxicity experiments showed that acrylamide could develop the genotoxicity and carcinogenicity properties like induction of micronuclei and aberrations in blood cells such as, spleen lymphocytes and peripheral red blood cells, DNA damage in Comet assay in various organs and transgenic gene mutation in liver [28]. Breaks, rearrangements and deletions in DNA, can increase risk of tumor if the DNA damage does not repair or promote into the cell death [28]. Our results showed that acrylamide induce DNA damage in human lymphocytes, these results are consistent with previously published data. Furthermore, several investigations demonstrated that acrylamide induced cancers in various organs including central nervous system, peritesticular mesothelium, mammary gland and thyroid, while the genotoxicity of acrylamide in all of mentioned organs have not been showed [29]. Although the carcinogenic effects of acrylamide have not been proven in many in vitro tests such as comet assay and even at bacterial gene mutation assays high concentrations [30]. Therefore, the use of human cells can be an advantage in identifying the genotoxic effects of acrylamide that has been considered in the current study.

Acrylamide is metabolized to glycidamide as active metabolite by the CYP450 in the body, where is known to be more reactive toward macromolecules such proteins, lipids and DNA than the parent acrylamide compound [31]. Most CYP family members such as CYP1A1, 1A2, P1B1, 2A6, 2B6 and 2E1 are expressed in human lymphocytes. It has been reported that gene expression levels above CYP subfamily were closely correlated within peripheral blood lymphocytes and within the liver [32]. It has been reported that once taken into the body, approximately 50% of acrylamide is metabolized to its epoxide metabolite glycidamide by the cytochrome CYP2E1, which is found in the human lymphocytes [33]. Previous studied have shown the relation between acrylamide-induced toxicity and oxidative stress [34]. Several investigations proved the ability of acrylamide in generation of ROS. ROS can react with the DNA molecule (the deoxyribose backbone and also both the pyrimidine and purine bases) [35]. DNA oxidative damage induced by ROS can play the first step involved in ageing, mutagenesis and carcinogenesis [35]. Our results indicated that acrylamide induce ROS formation in human lymphocytes, these results are consistent with previously published studies. Also, acrylamide-induced ROS generation and its active metabolite can attack to other important macromolecules such proteins and membrane lipids and induce lipid peroxidation and depletion of GSH [36]. Lipid peroxidation as a destructive chain reaction can lead to formation of more free radicals [37]. The adverse effects of free radicals and active metabolite of acrylamide are detoxified by the antioxidant agents such as GSH. GSH is an important intrinsic antioxidant capable of preventing adverse effect of free radicals such as ROS and reactive nitrogen species (RNS). In this process, GSH oxidized to GSSG [38]. Our result showed acrylamide led to depletion of GSH level of human lymphocytes which is consistent with previously published studies. However, it has been reported that acrylamide without directly damaging DNA, can induce chromosome aberration and sister chromatid exchange [30].

Lysosomes and mitochondria are necessary for cellular metabolism and building blocks. Moreover, these organelles do other functions as fundamental signaling platforms in the cell that control many key processes such as proliferation, autophagy and cell death [39]. The interdependence of lysosomes and mitochondria is underscored by many lines of evidence obtained from cells [39]. Many lysosomal storage diseases have reports of mitochondrial dysfunction, reciprocally most perturbations of lysosomal function in mitochondrial diseases have been reported [39]. Loss of mitochondrial function is associated with increased ROS production, decreased mitochondrial ATP and mitochondrial fragmentation [40], each potentially affecting lysosomes. It has been reported that lysosomal function is rescued by antioxidant agents, suggesting that oxidative damages play a significant role in the lysosomal phenotype arising as an outcome of ROS mitochondrial. It has been reported that acrylamide induces mitochondrial dysfunction associated with ROS formation in several in vitro and in vivo studies [41]. Also presented data in the current work consistent with other published studies, showed mitochondrial and lysosomal dysfunction induced by acrylamide in isolated human lymphocytes. Due to the oxidative stress, mitochondrial and lysosomal dysfunction are key feature of acrylamide cellular toxicity and also relation between these features together [40,42], therefore it is pivotal for cellular function to protect the mitochondria and lysosomes against oxidative damages.

The most important mechanisms that play a vital role during acrylamide-induced cytotoxicity and carcinogenicity are its metabolism to active intermediate glycidamide, mitochondrial dysfunction and ROS formation. Therefore, the use of dietary antioxidants such as EA, is very important to minimize the toxic effects associated with acrylamide. EA as an important component of vegetables and fruits and has been indicated to possess numerous antimutagenic and anticarcinogenic properties towards various carcinogenic agents [43]. Several studies have been designed to describe the broad anticarcinogenic and antimutagenic effects of EA [43]. The inhibition of CYP450 enzymes, especially CYP2E1 by EA is one of the proposed mechanisms [43]. CYP2E1 is important in the field of acrylamide-induced cytotoxicity and carcinogenicity [44]. It has been reported that daily intake of the EA decreases CYP2E1 protein level in the liver as a major enzyme in acrylamide activation [45]. Hence, EA administration might decrease acrylamide-induced cytotoxicity and carcinogenicity by inhibiting CYP2E1 and reduce reactive oxygen species by its antioxidant activity. Another mechanism for anticarcinogenic and antimutagenic effects of EA is its antioxidant potential. The antioxidant effect of EA is well known and this trait has been attributed to its free radical scavenging activity [46]. The existence of four hydroxyl functional groups and two lactone in EA chemical structure authorizes to scavenge a wide different of RNS and ROS [47]. Antioxidant activity of EA is not decreased after metabolism, its metabolites are also able of efficiently scavenging very free radicals, even faster than EA. This property of EA enhances antioxidant activity of EA at low concentrations, which is an desirable and unusual behavior for an common antioxidant [48]. Previous researches have been shown EA even at μM concentrations is effective in inhibiting lipid peroxidation [49]. Moreover, it has been reported the antioxidant properties of EA decrease mitochondrial dysfunction [50].

Conclusion

Our result in the current study showed that ellagic acid significantly reduce cytotoxicity, mitochondrial and lysosomal damages, oxidative parameters and DNA oxidation in isolated lymphocytes. Neuroprotective and hepatotoxicity effects of EA against acrylamide are proved in animal model [16,17] and this study proved promising effects of EA in inhibiting oxidative stress, mitochondrial/lysosomal damages, cytotoxicity and DNA oxidation in human lymphocytes. As a limitation in the current study, the obtained findings must be verified by other experimental models such as animal studies, to establish the protective effects of ellagic acid in human exposed with acrylamide.

Supporting information

S1 File

(PZF)

Click here for additional data file.^{(533K, pzf)}

S2 File

(PZF)

Click here for additional data file.^{(401K, pzf)}

S3 File

(PZF)

Click here for additional data file.^{(402K, pzf)}

S4 File

(PZF)

Click here for additional data file.^{(668K, pzf)}

S5 File

(PZF)

Click here for additional data file.^{(399K, pzf)}

S6 File

(PZF)

Click here for additional data file.^{(401K, pzf)}

S7 File

(PZF)

Click here for additional data file.^{(193K, pzf)}

S8 File

(PZF)

Click here for additional data file.^{(533K, pzf)}

S9 File

(PZF)

Click here for additional data file.^{(401K, pzf)}

Acknowledgments

The data provided in this article was extracted from the Pharm D. thesis of Dr. Elahe Baghal. The thesis was conducted under supervision of Dr. Ahmad Salimi at Department of Pharmacology and Toxicology, School of Pharmacy, Ardabil University of Medical Sciences, Ardabil, Iran.

Funding Statement

Ahmad Salimi This study was supported by Ardabil of Medical Sciences, Deputy of Research with ethics code IR.ARUMS.REC.1398.496.

Data Availability

All relevant data are within the manuscript and its Supporting Information files.

References

1. Rifai L, Saleh FA. A Review on Acrylamide in Food: Occurrence, Toxicity, and Mitigation Strategies. International Journal of Toxicology. 2020;39(2):93–102. 10.1177/1091581820902405 [PubMed] [CrossRef] [Google Scholar]

2. Tareke E, Rydberg P, Karlsson P, Eriksson S, Törnqvist M. Analysis of acrylamide, a carcinogen formed in heated foodstuffs. Journal of agricultural and food chemistry. 2002;50(17):4998–5006. 10.1021/jf020302f [PubMed] [CrossRef] [Google Scholar]

3. Dybing E, Farmer P, Andersen M, Fennell TR, Lalljie S, Müller D, et al. Human exposure and internal dose assessments of acrylamide in food. Food and Chemical Toxicology. 2005;43(3):365–410. 10.1016/j.fct.2004.11.004 [PubMed] [CrossRef] [Google Scholar]

4. Ahn J, Castle L, Clarke D, Lloyd AS, Philo M, Speck D. Verification of the findings of acrylamide in heated foods. Food Additives & Contaminants. 2002;19(12):1116–24. 10.1080/0265203021000048214 [PubMed] [CrossRef] [Google Scholar]

5. Kim H, Lee SG, Rhie J. Dermal and neural toxicity caused by acrylamide exposure in two Korean grouting workers: a case report. Annals of Occupational and Environmental Medicine. 2017;29(1):1–6. 10.1186/s40557-017-0207-7 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

6. Mojska H, Gielecińska I, Cendrowski A. Acrylamide content in cigarette mainstream smoke and estimation of exposure to acrylamide from tobacco smoke in Poland. Ann Agric Environ Med. 2016;23(3):456–61. 10.5604/12321966.1219187 [PubMed] [CrossRef] [Google Scholar]

7. Fennell TR, Friedman MA. Comparison of acrylamide metabolism in humans and rodents. Chemistry and Safety of Acrylamide in food: Springer; 2005. p. 109–16. [PubMed] [Google Scholar]

8. Settels E, Bernauer U, Palavinskas R, Klaffke HS, Gundert-Remy U, Appel KE. Human CYP2E1 mediates the formation of glycidamide from acrylamide. Archives of toxicology. 2008;82(10):717–27. 10.1007/s00204-008-0296-8 [PubMed] [CrossRef] [Google Scholar]

9. Kunnel SG, Subramanya S, Satapathy P, Sahoo I, Zameer F. Acrylamide induced toxicity and the propensity of phytochemicals in amelioration: a review. Central Nervous System Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Central Nervous System Agents). 2019;19(2):100–13. 10.2174/1871524919666190207160236 [PubMed] [CrossRef] [Google Scholar]

10. Mucci LA, Dickman P, Steineck G, Adami H-O, Augustsson K. Dietary acrylamide and cancer of the large bowel, kidney, and bladder: absence of an association in a population-based study in Sweden. British Journal of Cancer. 2003;88(1):84–9. 10.1038/sj.bjc.6600726 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

11. Jiang G, Zhang L, Wang H, Chen Q, Wu X, Yan X, et al. Protective effects of a Ganoderma atrum polysaccharide against acrylamide induced oxidative damage via a mitochondria mediated intrinsic apoptotic pathway in IEC-6 cells. Food & function. 2018;9(2):1133–43. [PubMed] [Google Scholar]

12. Mehri S, Karami HV, Hassani FV, Hosseinzadeh H. Chrysin reduced acrylamide-induced neurotoxicity in both in vitro and in vivo assessments. Iranian Biomedical Journal. 2014;18(2):101. 10.6091/ibj.1291.2013 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

13. Uthra C, Shrivastava S, Jaswal A, Sinha N, Reshi MS, Shukla S. Therapeutic potential of quercetin against acrylamide induced toxicity in rats. Biomedicine & Pharmacotherapy. 2017;86:705–14. 10.1016/j.biopha.2016.12.065 [PubMed] [CrossRef] [Google Scholar]

14. Maslanka R, Zadrag‐Tecza R, Kwolek K, Kwolek‐Mirek M. The effect of berry juices on the level of oxidative stress in yeast cells exposed to acrylamide. Journal of Food Biochemistry. 2016;40(5):686–95. [Google Scholar]

15. Evtyugin DD, Magina S, Evtuguin DV. Recent Advances in the Production and Applications of Ellagic Acid and Its Derivatives. A Review. Molecules. 2020;25(12):2745. 10.3390/molecules25122745 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

16. Karimi MY, Fatemi I, Kalantari H, Mombeini MA, Mehrzadi S, Goudarzi M. Ellagic Acid Prevents Oxidative Stress, Inflammation, and Histopathological Alterations in Acrylamide-Induced Hepatotoxicity in Wistar Rats. Journal of Dietary Supplements. 2019:1–12. [PubMed] [Google Scholar]

17. Goudarzi M, Mombeini MA, Fatemi I, Aminzadeh A, Kalantari H, Nesari A, et al. Neuroprotective effects of Ellagic acid against acrylamide-induced neurotoxicity in rats. Neurological research. 2019;41(5):419–28. 10.1080/01616412.2019.1576319 [PubMed] [CrossRef] [Google Scholar]

18. Salimi A, Vaghar-Moussavi M, Seydi E, Pourahmad J. Toxicity of methyl tertiary-butyl ether on human blood lymphocytes. Environmental Science and Pollution Research. 2016;23(9):8556–64. 10.1007/s11356-016-6090-x [PubMed] [CrossRef] [Google Scholar]

19. Soares BM, Araújo TMT, Ramos JAB, Pinto LC, Khayat BM, Bahia MDO, et al. Effects on DNA repair in human lymphocytes exposed to the food dye tartrazine yellow. Anticancer Research. 2015;35(3):1465–74. [PubMed] [Google Scholar]

20. Huang P, Zhang YH, Zheng XW, Liu YJ, Zhang H, Fang L, et al. Phenylarsine oxide (PAO) induces apoptosis in HepG2 cells via ROS-mediated mitochondria and ER-stress dependent signaling pathways. Metallomics. 2017;9(12):1756–64. 10.1039/c7mt00179g [PubMed] [CrossRef] [Google Scholar]

21. Salimi A, Roudkenar MH, Sadeghi L, Mohseni A, Seydi E, Pirahmadi N, et al. Selective anticancer activity of acacetin against chronic lymphocytic leukemia using both in vivo and in vitro methods: key role of oxidative stress and cancerous mitochondria. Nutrition and cancer. 2016;68(8):1404–16. 10.1080/01635581.2016.1235717 [PubMed] [CrossRef] [Google Scholar]

22. Eno CO, Zhao G, Venkatanarayan A, Wang B, Flores ER, Li C. Noxa couples lysosomal membrane permeabilization and apoptosis during oxidative stress. Free radical Biology and Medicine. 2013;65:26–37. 10.1016/j.freeradbiomed.2013.05.051 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

23. Boya P, Kroemer G. Lysosomal membrane permeabilization in cell death. Oncogene. 2008;27(50):6434–51. 10.1038/onc.2008.310 [PubMed] [CrossRef] [Google Scholar]

24. Beach DC, Giroux E. Inhibition of lipid peroxidation promoted by iron (III) and ascorbate. Archives of biochemistry and biophysics. 1992;297(2):258–64. 10.1016/0003-9861(92)90670-r [PubMed] [CrossRef] [Google Scholar]

25. Hissin PJ, Hilf R. A fluorometric method for determination of oxidized and reduced glutathione in tissues. Analytical biochemistry. 1976;74(1):214–26. 10.1016/0003-2697(76)90326-2 [PubMed] [CrossRef] [Google Scholar]

26. Jiang L, Cao J, An Y, Geng C, Qu S, Jiang L, et al. Genotoxicity of acrylamide in human hepatoma G2 (HepG2) cells. Toxicology in Vitro. 2007;21(8):1486–92. 10.1016/j.tiv.2007.06.011 [PubMed] [CrossRef] [Google Scholar]

27. Zamani E, Shokrzadeh M, Modanloo M, Shaki F. In Vitro Study Towards Role of Acrylamide-Induced Genotoxicity in Human Lymphocytes and the Protective Effect of L-Carnitine. Brazilian Archives of Biology and Technology. 2018;61. [Google Scholar]

28. Matoso V, Bargi-Souza P, Ivanski F, Romano MA, Romano RM. Acrylamide: A review about its toxic effects in the light of Developmental Origin of Health and Disease (DOHaD) concept. Food chemistry. 2019;283:422–30. 10.1016/j.foodchem.2019.01.054 [PubMed] [CrossRef] [Google Scholar]

29. Koyama N, Yasui M, Oda Y, Suzuki S, Satoh T, Suzuki T, et al. Genotoxicity of acrylamide in vitro: Acrylamide is not metabolically activated in standard in vitro systems. Environmental and molecular mutagenesis. 2011;52(1):11–9. 10.1002/em.20560 [PubMed] [CrossRef] [Google Scholar]

30. Koyama N, Sakamoto H, Sakuraba M, Koizumi T, Takashima Y, Hayashi M, et al. Genotoxicity of acrylamide and glycidamide in human lymphoblastoid TK6 cells. Mutation Research/Genetic Toxicology and Environmental Mutagenesis. 2006;603(2):151–8. [PubMed] [Google Scholar]

31. Keramat J, LeBail A, Prost C, Jafari M. Acrylamide in baking products: a review article. Food and Bioprocess Technology. 2011;4(4):530–43. [Google Scholar]

32. Furukawa M, Nishimura M, Ogino D, Chiba R, Ikai I, Ueda N, et al. Cytochrome p450 gene expression levels in peripheral blood mononuclear cells in comparison with the liver. Cancer science. 2004;95(6):520–9. 10.1111/j.1349-7006.2004.tb03243.x [PMC free article] [PubMed] [CrossRef] [Google Scholar]

33. Sumner SC, MacNeela JP, Fennell TR. Characterization and quantitation of urinary metabolites of [1, 2, 3-13C] acrylamide in rats and mice using carbon-13 nuclear magnetic resonance spectroscopy. Chemical Research in Toxicology. 1992;5(1):81–9. 10.1021/tx00025a014 [PubMed] [CrossRef] [Google Scholar]

34. Chen W, Shen Y, Su H, Zheng X. Hispidin derived from Phellinus linteus affords protection against acrylamide-induced oxidative stress in Caco-2 cells. Chemico-Biological Interactions. 2014;219:83–9. 10.1016/j.cbi.2014.05.010 [PubMed] [CrossRef] [Google Scholar]

35. Grigorov B. Reactive oxygen species and their relation to carcinogenesis. Trakia journal of sciences. 2012;10(3):83–92. [Google Scholar]

36. Birben E, Sahiner UM, Sackesen C, Erzurum S, Kalayci O. Oxidative stress and antioxidant defense. World Allergy Organization Journal. 2012;5(1):9–19. 10.1097/WOX.0b013e3182439613 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

37. Gahalain N, Chaudhary J, Kumar A, Sharma S, Jain A. Lipid peroxidation: an overview. International Journal of Pharmaceutical Sciences and Research. 2011;2(11):2757. [Google Scholar]

38. Kurutas EB. The importance of antioxidants which play the role in cellular response against oxidative/nitrosative stress: current state. Nutrition journal. 2015;15(1):1–22. [PMC free article] [PubMed] [Google Scholar]

39. Deus CM, Yambire KF, Oliveira PJ, Raimundo N. Mitochondria–lysosome crosstalk: from physiology to neurodegeneration. Trends in Molecular Medicine. 2020;26(1):71–88. 10.1016/j.molmed.2019.10.009 [PubMed] [CrossRef] [Google Scholar]

40. Demers-Lamarche J, Guillebaud G, Tlili M, Todkar K, Bélanger N, Grondin M, et al. Loss of mitochondrial function impairs lysosomes. Journal of biological chemistry. 2016;291(19):10263–76. 10.1074/jbc.M115.695825 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

41. Amo T, Sato S, Saiki S, Wolf AM, Toyomizu M, Gautier CA, et al. Mitochondrial membrane potential decrease caused by loss of PINK1 is not due to proton leak, but to respiratory chain defects. Neurobiology of disease. 2011;41(1):111–8. 10.1016/j.nbd.2010.08.027 [PubMed] [CrossRef] [Google Scholar]

42. Tan X, Li L, Wang J, Zhao B, Pan J, Wang L, et al. Resveratrol prevents acrylamide-induced mitochondrial dysfunction and inflammatory responses via targeting circadian regulator Bmal1 and Cry1 in hepatocytes. Journal of agricultural and food chemistry. 2019;67(31):8510–9. 10.1021/acs.jafc.9b03368 [PubMed] [CrossRef] [Google Scholar]

43. Celik G, Semiz A, Karakurt S, Arslan S, Adali O, Sen A. A comparative study for the evaluation of two doses of ellagic acid on hepatic drug metabolizing and antioxidant enzymes in the rat. BioMed Research International. 2013;2013. 10.1155/2013/358945 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

44. Ghanayem BI, McDaniel LP, Churchwell MI, Twaddle NC, Snyder R, Fennell TR, et al. Role of CYP2E1 in the epoxidation of acrylamide to glycidamide and formation of DNA and hemoglobin adducts. Toxicological sciences. 2005;88(2):311–8. 10.1093/toxsci/kfi307 [PubMed] [CrossRef] [Google Scholar]

45. García-Niño WR, Zazueta C. Ellagic acid: pharmacological activities and molecular mechanisms involved in liver protection. Pharmacological Research. 2015;97:84–103. 10.1016/j.phrs.2015.04.008 [PubMed] [CrossRef] [Google Scholar]

46. Ratnam DV, Ankola D, Bhardwaj V, Sahana DK, Kumar MR. Role of antioxidants in prophylaxis and therapy: A pharmaceutical perspective. Journal of controlled release. 2006;113(3):189–207. 10.1016/j.jconrel.2006.04.015 [PubMed] [CrossRef] [Google Scholar]

47. Ríos J-L, Giner RM, Marín M, Recio MC. A pharmacological update of ellagic acid. Planta medica. 2018;84(15):1068–93. 10.1055/a-0633-9492 [PubMed] [CrossRef] [Google Scholar]

48. Galano A, Francisco Marquez M, Pérez-González A. Ellagic acid: an unusually versatile protector against oxidative stress. Chemical research in toxicology. 2014;27(5):904–18. 10.1021/tx500065y [PubMed] [CrossRef] [Google Scholar]

49. Priyadarsini KI, Khopde SM, Kumar SS, Mohan H. Free radical studies of ellagic acid, a natural phenolic antioxidant. Journal of agricultural and food chemistry. 2002;50(7):2200–6. 10.1021/jf011275g [PubMed] [CrossRef] [Google Scholar]

50. Mohammad Khanlou E, Atashbar S, Kahrizi F, Shokouhi Sabet N, Salimi A. Bevacizumab as a monoclonal antibody inhibits mitochondrial complex II in isolated rat heart mitochondria: ameliorative effect of ellagic acid. Drug and Chemical Toxicology. 2020:1–8. 10.1080/01480545.2020.1715423 [PubMed] [CrossRef] [Google Scholar]

PLoS One. 2021; 16(2): e0247776.

Decision Letter 0

2021; 16(2): e0247776.

Published online 2021 Feb 26. doi:10.1371/journal.pone.0247776.r001

Soumen Bera, Academic Editor

8 Jan 2021

PONE-D-20-36110

Mitochondrial, Lysosomal and DNA Damages Induced by Acrylamide Attenuate by Ellagic Acid in Human Lymphocyte

PLOS ONE

Dear Dr. Salimi,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

We have received the comments from our reviewers on your manuscript 'Mitochondrial, Lysosomal and DNA Damages Induced by Acrylamide Attenuate by Ellagic Acid in Human Lymphocyte' submitted to PLOS One. The comments of the reviewers are included at the bottom of this email.

Based on the reviewers comments I have decided that your manuscript can be accepted for publication after you have carried out the corrections as suggested by the reviewer(s). When preparing your revised manuscript, carefully consider the reviewer comments and provide a point-by-point response.

Please submit your revised manuscript by Feb 13 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at gro.solp@enosolp. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see:http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Soumen Bera, PhD

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We suggest you thoroughly copyedit your manuscript for language usage, spelling, and grammar. If you do not know anyone who can help you do this, you may wish to consider employing a professional scientific editing service.

Whilst you may use any professional scientific editing service of your choice, PLOS has partnered with both American Journal Experts (AJE) and Editage to provide discounted services to PLOS authors. Both organizations have experience helping authors meet PLOS guidelines and can provide language editing, translation, manuscript formatting, and figure formatting to ensure your manuscript meets our submission guidelines. To take advantage of our partnership with AJE, visit the AJE website (http://learn.aje.com/plos/) for a 15% discount off AJE services. To take advantage of our partnership with Editage, visit the Editage website (www.editage.com) and enter referral code PLOSEDIT for a 15% discount off Editage services. If the PLOS editorial team finds any language issues in text that either AJE or Editage has edited, the service provider will re-edit the text for free.

Upon resubmission, please provide the following:

The name of the colleague or the details of the professional service that edited your manuscript
A copy of your manuscript showing your changes by either highlighting them or using track changes (uploaded as a *supporting information* file)
A clean copy of the edited manuscript (uploaded as the new *manuscript* file)

3. Thank you for stating in the text of your manuscript "Before blood sampling, the informed consent form was signed by the participants." Please also add this information to your ethics statement in the online submission form.

4. We note that you have included the phrase “data not shown” in your manuscript. Unfortunately, this does not meet our data sharing requirements. PLOS does not permit references to inaccessible data. We require that authors provide all relevant data within the paper, Supporting Information files, or in an acceptable, public repository. Please add a citation to support this phrase or upload the data that corresponds with these findings to a stable repository (such as Figshare or Dryad) and provide and URLs, DOIs, or accession numbers that may be used to access these data. Or, if the data are not a core part of the research being presented in your study, we ask that you remove the phrase that refers to these data.

5. We noticed you have some minor occurrence of overlapping text with the following previous publications, which needs to be addressed:

- http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-89132018000100426&lng=en&tlng=en

- https://doaj.org/article/5502805a216b4c0792fd0c32903148c5

- https://journals.sagepub.com/doi/10.1177/1091581820902405

In your revision ensure you cite all your sources (including your own works), and quote or rephrase any duplicated text outside the methods section. Further consideration is dependent on these concerns being addressed.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1:Yes

Reviewer #2:Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1:Yes

Reviewer #2:Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1:Yes

Reviewer #2:Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1:No

Reviewer #2:Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1:The manuscript by Baghal et al. describes the consequences of the exposure to human lymphocytes to acrylamide and the protection offered to those cells by the simultaneous treatment with ellagic acid. Acrylamide toxicity has been extensively studied, but both the use of primary human lymphocytes and description of the protection offered by ellagic acid are novel results. Several different endpoints where considered and the data supports the conclusions that ellagic acid could prevent mitochondrial damage and oxidative stress due to acrylamide exposure. The data is presented concisely, and the experiments were performed carefully. However, the manuscript would benefit from editing to improve grammar and wording as well as correct typographical errors. Specific issues are presented below:

1. Several qualities of acrylamide are provided by the manufacturer and it should be specified which was obtained for the described experiments.

2. Some additional information regarding participants in the study, such as gender and how were the healthy individuals recruited, would be useful.

3. The specific software used for the reported analyses should be specified in the Methods section.

4. The oxidative lesion 8-OHdG often occurs during handling and storage. Where there any specific precautions taken to limit this from happening? Also, the production of 8-OHdG was not formally determined, just the steady state levels. It is possible that it was the removal of the lesion that was affected by the treatments.

5. The Discussion could be shortened to provide less general background and instead focus on the significance and implications of the data obtained.

6. In the References, reference 1 lacks details and the formatting of many references requires correction.

Reviewer #2:Comment

The work presented provides evidence that ellagic protects lymphocytes from the toxic effects of ellagic acid. The authors show that several end points for mitochondrial function and oxidative stress induced by acrylamide are inhibited by ellagic acid.

1. The author need to provide more physiological evidence for there findings in a cell or animal model to support the in vitro lymphocyte data presented.

2. Can the authors provided evidence for the mechanism of ellagic acid and how it blocks the toxicity of acrylamide?

3. Is the protection by ellagic acid related to its antioxidant properties or some other mechanism?

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1:No

Reviewer #2:No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool,https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS atgro.solp@serugif. Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: Resoponse to reviewers.doc

Click here for additional data file.^{(46K, doc)}

PLoS One. 2021; 16(2): e0247776.

Decision Letter 1

2021; 16(2): e0247776.

Published online 2021 Feb 26. doi:10.1371/journal.pone.0247776.r003

Soumen Bera, Academic Editor

15 Feb 2021

Mitochondrial, Lysosomal and DNA Damages Induced by Acrylamide Attenuate by Ellagic Acid in Human Lymphocyte

PONE-D-20-36110R1

Dear Dr. Salimi,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at gro.solp@gnillibrohtua.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact gro.solp@sserpeno.

Kind regards,

Soumen Bera, PhD

Academic Editor

PLOS ONE

PLoS One. 2021; 16(2): e0247776.

Acceptance letter

2021; 16(2): e0247776.

Published online 2021 Feb 26. doi:10.1371/journal.pone.0247776.r004

Soumen Bera, Academic Editor

19 Feb 2021

PONE-D-20-36110R1

Mitochondrial, Lysosomal and DNA Damages Induced by Acrylamide Attenuate by Ellagic Acid in Human Lymphocyte

Dear Dr. Salimi:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact gro.solp@sserpeno.

If we can help with anything else, please email us at gro.solp@enosolp.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Soumen Bera

Academic Editor

PLOS ONE

Articles from PLOS ONE are provided here courtesy of PLOS